1. Home
  2. MCHX vs TLSA Comparison

MCHX vs TLSA Comparison

Compare MCHX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.34

Market Cap

67.3M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.92

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
TLSA
Founded
2003
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.3M
145.1M
IPO Year
2003
2017

Fundamental Metrics

Financial Performance
Metric
MCHX
TLSA
Price
$1.34
$0.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
39.6K
520.2K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,291,000.00
N/A
Revenue This Year
$5.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$0.76
52 Week High
$2.04
$2.35

Technical Indicators

Market Signals
Indicator
MCHX
TLSA
Relative Strength Index (RSI) 40.05 44.89
Support Level N/A $0.90
Resistance Level $1.73 $1.20
Average True Range (ATR) 0.14 0.08
MACD -0.03 -0.00
Stochastic Oscillator 36.62 50.89

Price Performance

Historical Comparison
MCHX
TLSA

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: